On April 18, 2026, President Donald J. Trump signed an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, including conditions described as devastating, complex, and treatment-resistant. The order specifically targets barriers to psychedelic drugs as potential therapies and mandates coordinated action across federal agencies to expand research and clinical access.
The Executive Order instructs the Food and Drug Administration (FDA) Commissioner to provide Commissioner’s National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designations for treating serious mental illnesses and meet the criteria of the National Priority Voucher Program. This mechanism aims to prevent administrative delays in the FDA’s review process for promising treatments.
the order directs the FDA and the Drug Enforcement Agency (DEA) to establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds, that are under FDA review and have met basic safety requirements under the Right to Try Act. This provision seeks to enable patients with serious mental illness to obtain experimental treatments outside traditional clinical trial frameworks when standard therapies have failed.
The order requires HHS to allocate $50 million through the Advanced Research Projects for Health (ARPA-H) program to match investments made by state governments in advancing research into psychedelic programs for populations with serious mental illness. This funding is intended to leverage state-level initiatives and expand the evidence base for emerging therapies.
the Executive Order mandates collaboration between HHS, the FDA, the Department of Veterans Affairs (VA), and the private sector to increase clinical trial participation and evidence generation surrounding experimental psychedelic therapies. This emphasis on veteran populations reflects documented disparities in mental health outcomes, including elevated suicide rates and limited response to conventional treatments among former service members.
In a public statement accompanying the order, Americans for Ibogaine CEO W. Bryan Hubbard described the action as the culmination of a national movement to integrate ibogaine into the U.S. Healthcare system, calling it “the moonshot of our time.” Former Texas Governor and Americans for Ibogaine Chairman Rick Perry highlighted the impact of ibogaine on veterans, noting that many had previously been forced to seek care outside the United States. American Legion National Commander Dan K. Wiley expressed hope that advancements in research would provide a pathway to improved mental health outcomes for veterans and their families.
The Executive Order builds upon prior federal interest in psychedelic research, including ongoing clinical trials investigating substances like psilocybin and MDMA for conditions such as treatment-resistant depression and post-traumatic stress disorder (PTSD). By directing agencies to reduce regulatory barriers and expand access pathways, the order aims to accelerate the evaluation of these compounds under rigorous scientific standards.
Implementation of the order will involve interagency coordination to develop guidance for patients, healthcare providers, and researchers seeking to participate in or access investigational psychedelic therapies. Officials have indicated that detailed implementation plans will be released in the coming weeks, with updates expected from HHS, the FDA, and the DEA regarding specific timelines and eligibility criteria.
As the federal government moves to operationalize the directives outlined in the Executive Order, stakeholders across the mental health, veterans’ advocacy, and medical research communities are monitoring developments closely. The coming months will be critical in determining how effectively the order translates into expanded research opportunities and patient access to novel treatments for serious mental illness.